Goodman Financial Corp Buys 35,972 Shares of QuidelOrtho Co. (NASDAQ:QDEL)

Goodman Financial Corp boosted its stake in shares of QuidelOrtho Co. (NASDAQ:QDEL) by 13.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 306,784 shares of the company’s stock after purchasing an additional 35,972 shares during the period. QuidelOrtho comprises 2.9% of Goodman Financial Corp’s portfolio, making the stock its 18th largest holding. Goodman Financial Corp owned about 0.46% of QuidelOrtho worth $13,667,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its holdings in shares of QuidelOrtho by 13.9% during the 4th quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 14,071 shares of the company’s stock valued at $627,000 after buying an additional 1,712 shares during the period. Magnetar Financial LLC lifted its holdings in QuidelOrtho by 207.8% in the fourth quarter. Magnetar Financial LLC now owns 877,307 shares of the company’s stock valued at $39,084,000 after acquiring an additional 592,307 shares during the period. Maryland State Retirement & Pension System lifted its holdings in QuidelOrtho by 7.3% in the fourth quarter. Maryland State Retirement & Pension System now owns 25,233 shares of the company’s stock valued at $1,124,000 after acquiring an additional 1,723 shares during the period. Thrivent Financial for Lutherans boosted its position in QuidelOrtho by 12.2% in the fourth quarter. Thrivent Financial for Lutherans now owns 50,947 shares of the company’s stock worth $2,270,000 after purchasing an additional 5,540 shares during the last quarter. Finally, Corient Private Wealth LLC grew its stake in shares of QuidelOrtho by 10.6% during the 4th quarter. Corient Private Wealth LLC now owns 6,874 shares of the company’s stock valued at $306,000 after purchasing an additional 661 shares during the period. Hedge funds and other institutional investors own 99.00% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on QDEL. UBS Group raised their price objective on shares of QuidelOrtho from $43.00 to $45.00 and gave the stock a “neutral” rating in a report on Thursday, February 13th. Royal Bank of Canada dropped their price target on shares of QuidelOrtho from $64.00 to $61.00 and set an “outperform” rating on the stock in a research note on Thursday, February 13th. StockNews.com lowered QuidelOrtho from a “buy” rating to a “hold” rating in a research note on Saturday, February 15th. Jefferies Financial Group started coverage on QuidelOrtho in a research report on Tuesday, December 10th. They set a “hold” rating and a $43.00 target price on the stock. Finally, Citigroup upgraded QuidelOrtho from a “neutral” rating to a “buy” rating and upped their price target for the stock from $44.00 to $50.00 in a research report on Wednesday, December 11th. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $51.20.

QuidelOrtho Stock Up 1.1 %

QDEL opened at $35.16 on Friday. The stock has a market cap of $2.37 billion, a price-to-earnings ratio of -1.16 and a beta of 0.10. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.69 and a current ratio of 1.22. The firm’s fifty day moving average is $40.98 and its 200 day moving average is $41.74. QuidelOrtho Co. has a fifty-two week low of $29.74 and a fifty-two week high of $49.45.

QuidelOrtho (NASDAQ:QDEL) last announced its quarterly earnings data on Wednesday, February 12th. The company reported $0.63 EPS for the quarter, missing the consensus estimate of $1.07 by ($0.44). QuidelOrtho had a negative net margin of 72.84% and a positive return on equity of 3.78%. On average, sell-side analysts forecast that QuidelOrtho Co. will post 2.3 earnings per share for the current fiscal year.

About QuidelOrtho

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.